Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Advanced Neurology Specialists

Neither a doctor nor a teaching hospital

Research payments

$507,061

55 payments

Through program year 2024, Advanced Neurology Specialists is reported as receiving $507,061 in research payments, across 55 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $19 1
2023 Research $543 2
2022 Research $2,611 4
2021 Research $190,010 4
2020 Research $184,024 10
2019 Research $129,854 34

Breakdown

Who paid Research payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $381,635 7 payments
  2. Adamas Pharmaceuticals, Inc. $84,884 34 payments
  3. Biogen, Inc. $32,619 9 payments
  4. Merck Sharp & Dohme Corporation $6,100 3 payments
  5. Roche Products Limited $1,823 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $350,937 5 payments
  2. A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study to Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment $61,969 23 payments
  3. A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $29,698 1 payment
  4. A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment $22,916 11 payments
  5. Plegridy Observational Program $17,159 3 payments
  6. Dimethyl Fumarate (DMF) Observational Study $14,315 3 payments
  7. HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease. $6,100 3 payments
  8. Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment $1,823 2 payments
  9. A 12 Month Randomized Rater and Dose Blinded Study to Compare the Efficacy and Safety of Fingolimod Twenty Five Hundredth of A MG and Half of A MG Administered Orally Once Daily With Glatiramer Acetate 20 MG Administered Subcutaneously Once Daily in Patie $1,000 1 payment
  10. A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) $753 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record